Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness.
AuthorCavaliere, Vincent S
DiPaula, Bethany A
Wehring, Heidi J
Love, Raymond C
Richardson, Charles M
Kearns, Ann Marie
Kelly, Deanna L
MetadataShow full item record
AbstractIntroduction: Patients with severe mental illness are falsely characterized as aggressive by the media, perpetuating stigma. While exaggerated, some patients with severe mental illness are more aggressive without treatment. Clozapine may have a unique anti-aggressive effect in patients with schizophrenia-related disorders, independent of antipsychotic or sedative effects. Limited data in forensic and involuntary committed patients is currently available. Purpose: This study evaluates clozapine's effects on hostility and aggression in court-ordered Black patients. Methods: This study analyzes a subgroup of Black patients from a larger prospective 24-week open-label clozapine study. All patients were involuntarily committed and enrolled from two participating state psychiatric hospitals. The primary outcome measured was total use of ‘as needed’ (PRN) or ‘immediate need’ (STAT) medications for aggression/hostility. Secondary outcomes included number and duration of seclusion and restraint (S/R) episodes, and changes in Brief Psychiatric Rating Scale (BPRS) hostility factor score. Results: Sixty-nine patients were included in our analysis. Significant reductions were noted in PRN/STAT medication use over time (χ2 = 6.90; p = 0.008) and the BPRS hostility factor score was reduced by 30% over the 24 weeks (F = 4.34, df = 62, p = 0.002). Conclusions: Treatment with clozapine effectively reduced hostility and aggression within this cohort of involuntarily committed Black patients with mental illness compared to baseline. Specifically, it helped lower the total number of PRN/STAT medication administrations and improved clinician-rated hostility factor scores on the BPRS. Our findings are pertinent as data in forensic settings is lacking and Black patients have been infrequently included in large prospective clinical trials with clozapine. ClinicalTrials.gov identifier: NCT02404155.
Rights/TermsCopyright © 2022. Published by Elsevier B.V.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18532
- A systematic review of the evidence of clozapine's anti-aggressive effects.
- Authors: Frogley C, Taylor D, Dickens G, Picchioni M
- Issue date: 2012 Oct
- Violence and schizophrenia: clozapine as a specific antiaggressive agent.
- Authors: Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC
- Issue date: 1995
- Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia.
- Authors: Ifteni P, Szalontay AS, Teodorescu A
- Issue date: 2017 Mar/Apr
- Clozapine in Reducing Aggression and Violence in Forensic Populations.
- Authors: Patchan K, Vyas G, Hackman AL, Mackowick M, Richardson CM, Love RC, Wonodi I, Sayer MA, Glassman M, Feldman S, Kelly DL
- Issue date: 2018 Mar
- The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study.
- Authors: Spivak B, Shabash E, Sheitman B, Weizman A, Mester R
- Issue date: 2003 Jul